Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Theralase Technologies Inc (TLT.VN)

Theralase Technologies Inc (TLT.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Theralase Technologies Inc 41 Hollinger Road Toronto ON M4B 3G4 CAN

https://www.theralase.com P: 416-699-5273 F: 416-699-5250

Sector:

Medical

INDUSTRY GROUPING:

TSX Medical Devices

Description:

Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.

Key Statistics

Overview:

Market Capitalization, $K 41,129
Shares Outstanding, K 257,058
Annual Sales, $ 1,033 K
Annual Net Income, $ -4,256 K
Last Quarter Sales, $ 280 K
Last Quarter Net Income, $ -1,012 K
60-Month Beta -0.45
% of Institutional Shareholders 0.20%

Growth:

1-Year Return -38.00%
3-Year Return -51.52%
5-Year Return -11.11%
5-Year Revenue Growth 1.40%

Per-Share Information:

Most Recent Earnings 0.00 on 11/10/25
Next Earnings Date 11/26/25
Earnings Per Share ttm -0.02
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year -14.29%
Dividend Payout Ratio 0.00%

TLT.VN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -269.41%
Return-on-Assets % -139.83%
Profit Margin % -411.84%
Debt/Equity 0.09
Price/Sales 40.29
Price/Book 37.64
Book Value/Share 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar